Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC

Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC

Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a conventional DA 7+3 protocol (45mg/m2 Daunorubicin).

Randomized comparison of the two protocols.

Inclusion Criteria:

• Diagnosis of AML
• age >60
• no previous Chemo for AML
• informed consent
• Karnofsky >70

Exclusion Criteria:

• AML M3
• uncontrolled Sepsis
• uncontrolled HYpertension
• respiratory failure
• heart-failure NYHA IV, recent myocardial infarction
• severe organ dysfunction of liver, kidneys,
• HIV -infection or active Hepatitis B,C